Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
Previous Symbol
CUSIP18946410
Phone303-625-5000
Debt
Debt-to-Equity Ratio2.46
Current Ratio9.03
Quick Ratio8.46
Price-To-Earnings
Trailing P/E Ratio-2.98
Forward P/E Ratio-2.29
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.51 million
Price / Sales14.49
Cash FlowN/A
Price / CashN/A
Book Value$7.50 per share
Price / Book2.03
Profitability
EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-390.65%
Return on Equity-108.92%
Return on Assets-40.59%
Miscellaneous
Employees360
Outstanding Shares52,710,000
Market Cap$824.94 million
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.60) by $0.11. The biopharmaceutical company earned $22.76 million during the quarter, compared to analyst estimates of $30.11 million. Clovis Oncology had a negative return on equity of 108.92% and a negative net margin of 390.65%. The business's revenue for the quarter was up 35.4% on a year-over-year basis. During the same period last year, the company earned ($1.24) EPS. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
14 brokerages have issued 12 month price objectives for Clovis Oncology's shares. Their forecasts range from $16.00 to $110.00. On average, they anticipate Clovis Oncology's share price to reach $57.0520 in the next twelve months. This suggests a possible upside of 273.9% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. Cann analysts commented, "The initial data for the TRITON2 study in patients with metastatic, HR-deficient, castration-resistant prostate cancer are based on small patient numbers, but are very encouraging for patients with BRCA mutations. The 44% ORR for these patients compares favorably to the reference literature. In addition, screening data using less invasive cfDNA plasma testing could help identify more patients eligible for Rubraca treatment in the prostate setting. We have not included any sales or earnings in our outlook from Rubraca in the prostate setting by 2022 due to its stage of development, but we are encouraged by these initial TRITON2 data. Our financial outlook for Clovis’ revenue remains unchanged for 2018-2022." (10/19/2018)
- 2. According to Zacks Investment Research, "Clovis’ Rubraca is progressing well and registering sales growth. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, Clovis received approval for the label expansion in second-line maintenance setting in the United States, irrespective of BRCA-mutation, and as monotherapy in Europe. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. The company has stopped development of rociletinib upon receiving a CRL and lucitanib on negative results. Any further setback will adversely affect the company’s prospects. Moreover, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Meanwhile, Rubraca is set to face intense competition from currently marketed PARP inhibitors. Clovis’ shares have underperformed the industry so far this year." (7/10/2018)
Has Clovis Oncology been receiving favorable news coverage?
News headlines about CLVS stock have trended somewhat positive on Tuesday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clovis Oncology earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the immediate future.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), ACADIA Pharmaceuticals (ACAD), Myokardia (MYOK), Akcea Therapeutics (AKCA), Allakos (ALLK), Heron Therapeutics (HRTX) and Xencor (XNCR).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (2.68%), Emerald Advisers Inc. PA (0.73%), Emerald Mutual Fund Advisers Trust (0.62%), State of New Jersey Common Pension Fund D (0.55%), Rice Hall James & Associates LLC (0.28%) and Prudential Financial Inc. (0.20%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which institutional investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Los Angeles Capital Management & Equity Research Inc., C WorldWide Group Holding A S, Russell Investments Group Ltd., Wealthstreet Investment Advisors LLC, Rice Hall James & Associates LLC and Rhumbline Advisers. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which institutional investors are buying Clovis Oncology stock?
CLVS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Prudential Financial Inc., Hsbc Holdings PLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers Inc. PA, Fox Run Management L.L.C., Essex Investment Management Co. LLC and Bank of Montreal Can. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $15.26.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $824.94 million and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
